<DOC>
	<DOCNO>NCT00002895</DOCNO>
	<brief_summary>RATIONALE : It yet know treatment recurrent ovarian epithelial , fallopian tube , primary peritoneal cancer effective begin blood level CA 125 become elevate rather wait indicator disease recurrence . PURPOSE : This randomized phase III trial study early chemotherapy base blood level CA 125 alone see well work compare chemotherapy base conventional clinical indicator patient recurrent ovarian epithelial , fallopian tube , primary peritoneal cancer .</brief_summary>
	<brief_title>Early Chemotherapy Based CA 125 Level Alone Compared With Delayed Chemotherapy Treating Patients With Recurrent Ovarian Epithelial , Fallopian Tube , Primary Peritoneal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare benefit early chemotherapy base CA 125 level v chemotherapy base conventional clinical indicator patient relapse ovarian epithelial , fallopian tube , primary peritoneal cancer . - Compare overall survival patient treat regimen . - Compare quality life patient treat regimen . OUTLINE : This randomize , multicenter study . Patients whose CA 125 level rise two time upper limit normal randomize one two treatment arm . - Arm I : The clinician inform initial rise CA 125 level . A confirmatory test perform immediately . Within 4 week initial CA 125 elevation , patient second confirm elevation receive treatment recurrent disease accord standard local practice . Patients normal CA 125 confirmatory test receive treatment clinically indicate . - Arm II : The clinician blind CA 125 result . Patients undergo normal monitoring . When clinically indicate , patient commence treatment accord standard local practice . Quality life assess baseline , follow-up visit , , treatment institute , chemotherapy course . Patients follow every 3 month . PROJECTED ACCRUAL : A total 1,400 patient accrue study .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm ovarian epithelial , fallopian tube , primary peritoneal cancer Achieved complete remission normal CA 125 firstline platinumcontaining chemotherapy Prior participation follow clinical trial allow : MRCICON2 ( carboplatin v cyclophosphamide , doxorubicin , cisplatin advanced disease ) MRCICON3 ( paclitaxel carboplatin firstline therapy advance disease ) MRCICON5 ( carboplatin paclitaxel v triplet sequential doublet combination chemotherapy ) No prior participation MRCICON1 ( adjuvant chemotherapy earlystage ovarian cancer ) PATIENT CHARACTERISTICS : Age : Not specify Performance status : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : No prior concurrent malignancy within past 5 year likely preclude study treatment comparison except nonmelanoma skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>primary peritoneal cavity cancer</keyword>
	<keyword>fallopian tube cancer</keyword>
</DOC>